Passa al contenuto
Merck

MicroRNAs in endometrial cancers from black and white patients.

American journal of obstetrics and gynecology (2014-09-02)
G Larry Maxwell, Yutaka Shoji, Kathleen Darcy, Tracy Litzi, Andrew Berchuck, Chad A Hamilton, Thomas P Conrads, John I Risinger
ABSTRACT

Previous studies have identified differences in gene mutations among endometrial cancers from whites and blacks suggesting that differences in tumor biology may explain racial disparities in patient outcome. Micro RNAs (miRNAs) have emerged as regulators of transcript expression and their aberrant expression has been discovered in many diseases, including endometrial cancer. We performed quantitative polymerase chain reaction-based analysis in a set of endometrial cancers to identify whether there are racial differences in miRNA expression. Tumor cells from 50 stage-I endometrioid endometrial cancer specimens from 41 white and 9 black patients were prepared by laser microdissection and miRNA extracts were analyzed using TaqMan (Life Technologies, Carlsbad, CA) low-density arrays. Statistically significant, differentially expressed miRNAs between blacks and whites were identified using multidimensional scaling, Wilcoxon testing, and analysis of variance. There were no global differences in miRNA expression between endometrial cancers from 41 white and 9 black patients. To minimize potential bias introduced by unbalanced sample size, we performed a subset analysis with stage- and histology-matched specimens from 9 whites and 9 blacks that identified 18 differentially abundant miRNAs (>2-fold at P < .005). Quantitative polymerase chain reaction validated miRNA-337-3p in an independent set of endometrial cancer specimens from 23 white and 24 black women. There were no racial differences in hsa-miR-337-3p expression in normal endometrium. These data indicate that hsa-mir-337-3p is more frequently down-regulated in endometrial cancers from whites compared to blacks. Future studies are focused on determining the phenotypic impact of miR-337-3p and whether its differential expression is associated with clinical outcome.

MATERIALI
N° Catalogo
Marchio
Descrizione del prodotto

Sigma-Aldrich
Sodio dodecil solfato, BioReagent, suitable for electrophoresis, for molecular biology, ≥98.5% (GC)
Sigma-Aldrich
Sodio dodecil solfato, ≥99.0% (GC), dust-free pellets
Sigma-Aldrich
Sodio dodecil solfato, BioUltra, for molecular biology, 10% in H2O
Sigma-Aldrich
Sodio dodecil solfato, ACS reagent, ≥99.0%
Sigma-Aldrich
Sodio dodecil solfato, BioUltra, for molecular biology, 20% in H2O
Sigma-Aldrich
Sodio dodecil solfato, ReagentPlus®, ≥98.5% (GC)
Sigma-Aldrich
Sodio dodecil solfato, BioUltra, for molecular biology, ≥99.0% (GC)
Supelco
Sodio dodecil solfato, dust-free pellets, suitable for electrophoresis, for molecular biology, ≥99.0% (GC)
Sigma-Aldrich
Sodio dodecil solfato, BioXtra, ≥99.0% (GC)
Sigma-Aldrich
Sodio dodecil solfato, ≥98.0% (GC)
Sigma-Aldrich
Sodio dodecil solfato, 92.5-100.5% based on total alkyl sulfate content basis
Supelco
Sodio dodecil solfato, suitable for ion pair chromatography, LiChropur, ≥99.0%
Sigma-Aldrich
Sodio dodecil solfato, tested according to NF, mixture of sodium alkyl sulfates consisting mainly of sodium dodecyl sulfate
Sigma-Aldrich
Sodio dodecil solfato, ≥90% ((Assay))
Sodio dodecil solfato, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Sodio dodecil solfato, BioReagent, suitable for electrophoresis, for molecular biology, ≥98.5% (GC), free-flowing, Redi-Dri